Q-omics provides the consensus-scored MTCO1P46 profile across patient tissues and cancer cell-line models. MTCO1P46 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MTCO1P46 is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, MTCO1P46 RNA expression shows 10,955 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, KIRC, and GBM as cancer lineages where MTCO1P46 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTCO1P46 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTCO1P46 survival associations across molecular data types. MTCO1P46 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTCO1P46 RNA expression–survival associations across cancer types. High MTCO1P46 expression shows unfavorable associations in MESO, LIHC, LUSC and BRCA, but favorable associations in SKCM and LAML. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .012). Together, the overview and detailed table identify MESO as the clearest survival context for MTCO1P46 RNA expression.
This table summarizes MTCO1P46 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MTCO1P46. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTCO1P46 shows lower tumor expression in KIRC, HNSC, PAAD and STAD and higher tumor expression in KICH. The KIRC box plot shows higher MTCO1P46 RNA expression in normal versus tumor tissue (log2 FC = −0.037, t-test p = .001).
This table shows molecular features associated with MTCO1P46 in patient tissues and cancer cell lines. In patient samples, MTCO1P46 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
